Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kite Pharma has entered into a collaboration agreement with the National Cancer Institute (NCI) to develop targeted cellular therapy for the treatment of multiple cancers.
Subscribe to our email newsletter
Under the cooperative research and development agreement, Kite will develop engineered peripheral blood autologous T cell therapeutics (eACT), which contains proprietary tumor-specific T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs).
Clinical studies demonstrated that these engineered peripheral blood T cells have been associated with significant and durable objective clinical responses in cancer patients with advanced metastatic disease including refractory melanoma, sarcoma, lymphoma and leukemia.
The collaboration, at NCI led by Steven A. Rosenberg, will also enable Kite to have access to the current and future clinical product pipeline of autologous peripheral blood T cells, engineered with the NCI’s TCRs and CARs, directed to multiple hematological and solid tumor types.
Kite president and CEO Aya Jakobovits said the company has recognized ACT/TCR/CAR as a potential therapeutic approach to treat cancer patients.
"We are very pleased to partner with Rosenberg and his team, whose vision, innovation, and groundbreaking work in the field of cancer immunotherapy was instrumental in the development of autologous cell therapy and realization of its potential for cancer treatment," Jakobovits added.
"Kite will focus its efforts and resources to advance the NCI clinical product pipeline into multi-center studies aimed at successful registration and commercialization."